Breast Cancer Clinical Trials in Nashville

Showing 401-420 of 605 trials

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

NCT03205176

This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.

Malignant Solid TumorsLymphomaOvarian Cancer+3 more

AstraZeneca49 participantsStarted Jun 2017

Sarasota, Florida, United States • Oklahoma City, Oklahoma, United States • Nashville, Tennessee, United States +1 more locations

UNKNOWNPhase 1< 1 mile

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

NCT02500199

Part 1: to assess the safety and tolerability of pyrotinib and to define the maximum tolerated dose (MTD) of pyrotinib in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors (metastatic breast cancer, gastric cancer, or other solid tumors that have no targeted agent as standard of care). Part 2: to estimate the overall response rate (ORR) for patients with HER2-positive metastatic breast cancer (mBC) and HER2 mutant non-small cell lung cancer (NSCLC) treated at the RP2D (or MTD).

Breast CancerGastric CancerSolid Tumors+1 more

Hengrui Therapeutics, Inc.50 participantsStarted Jun 2015

Orange, California, United States • Sacramento, California, United States • Sarasota, Florida, United States +7 more locations

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Breast Cancer Trials in Other Cities

NBRST: Prospective Neo-adjuvant REGISTRY Trial

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer

PCA062 in pCAD-positive Tumors.

Other Conditions in Nashville